Profile data is unavailable for this security.
About the company
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
- Revenue in USD (TTM)0.00
- Net income in USD-22.34m
- Incorporated2018
- Employees13.00
- LocationMaia Biotechnology Inc444 West Lake StreetSuite 1700, Suite 1700CHICAGO 60606United StatesUSA
- Phone+1 (312) 416-8592
- Fax+1 (302) 655-5049
- Websitehttps://maiabiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanrong Biotechnology Corp | 1.32m | -5.08m | 60.02m | 3.00 | -- | -- | -- | 45.31 | -15.40 | -15.40 | 4.10 | -11.40 | 4.45 | -- | 11.81 | 441,576.70 | -1,705.30 | -- | -- | -- | -- | -- | -383.32 | -- | 0.0315 | -16.22 | -- | -- | 91.44 | -- | -86.62 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -82.71m | 62.26m | 63.00 | -- | 0.5124 | -- | -- | -1.58 | -1.58 | 0.00 | 2.28 | 0.00 | -- | -- | 0.00 | -46.29 | -21.46 | -49.90 | -22.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 14.87 | -- | 43.14 | -- |
| Beyondspring Inc | 0.00 | -7.83m | 62.46m | 40.00 | -- | -- | -- | -- | -0.1942 | -0.0148 | 0.00 | -0.788 | -- | -- | -- | 0.00 | -- | -61.84 | -- | -81.30 | -- | -- | -- | -6,633.90 | -- | -- | -- | -- | -- | -- | 35.26 | -- | 123.69 | -- |
| Annovis Bio Inc | 0.00 | -24.88m | 63.61m | 8.00 | -- | 3.68 | -- | -- | -1.41 | -1.41 | 0.00 | 0.6517 | 0.00 | -- | -- | 0.00 | -157.74 | -116.87 | -221.93 | -138.75 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 56.25 | -- | -- | -- |
| Fractyl Health Inc | 3.00k | -122.20m | 68.28m | 107.00 | -- | -- | -- | 22,760.41 | -2.27 | -2.27 | 0.00006 | -0.024 | 0.00002 | -- | -- | 28.04 | -101.33 | -78.52 | -118.18 | -97.44 | 100.00 | -- | -4,073,233.00 | -122,747.90 | -- | -31.40 | 1.12 | -- | -22.50 | -- | 25.29 | -- | 78.65 | -- |
| Adicet Bio Inc | 0.00 | -115.01m | 68.29m | 152.00 | -- | 0.3399 | -- | -- | -20.22 | -20.22 | 0.00 | 20.98 | 0.00 | -- | -- | 0.00 | -59.52 | -36.24 | -66.08 | -39.41 | -- | -- | -- | -813.80 | -- | -- | 0.0088 | -- | -- | -- | 17.90 | -- | 32.77 | -- |
| Gain Therapeutics Inc | 0.00 | -19.39m | 68.46m | 23.00 | -- | 10.84 | -- | -- | -0.6364 | -0.6364 | 0.00 | 0.1643 | 0.00 | -- | -- | 0.00 | -153.07 | -79.58 | -234.03 | -95.32 | -- | -- | -- | -19,975.78 | -- | -33.79 | 0.067 | -- | -100.00 | -- | 8.34 | -- | 10.39 | -- |
| Maia Biotechnology Inc | 0.00 | -22.34m | 69.25m | 13.00 | -- | 1,546.04 | -- | -- | -0.7504 | -0.7504 | 0.00 | 0.0012 | 0.00 | -- | -- | 0.00 | -212.50 | -208.29 | -602.02 | -373.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -17.61 | -- | -- | -- |
| Coeptis Therapeutics Holdings Inc | 500.99k | -11.28m | 70.18m | 5.00 | -- | 6.06 | -- | 140.09 | -3.47 | -3.47 | 0.1476 | 2.01 | 0.0433 | -- | 11.65 | 100,198.00 | -118.13 | -42.24 | -167.86 | -44.32 | 72.96 | -- | -2,727.81 | -- | -- | -73.66 | 0.0224 | -- | -- | -- | 53.85 | -- | -- | -- |
| XBiotech Inc | 0.00 | -29.16m | 73.78m | 88.00 | -- | 0.4416 | -- | -- | -0.9566 | -0.9566 | 0.00 | 5.48 | 0.00 | -- | -- | 0.00 | -15.25 | -7.74 | -16.08 | -8.02 | -- | -- | -- | -187.68 | -- | -- | 0.00 | -- | -- | -- | -56.90 | -- | 44.92 | -- |
| Ibio Inc | 500.00k | -20.11m | 73.87m | 20.00 | -- | 0.8205 | -- | 147.74 | -1.44 | -1.44 | 0.0232 | 2.77 | 0.0113 | -- | 15.38 | 25,000.00 | -45.35 | -30.90 | -50.81 | -37.76 | -- | -- | -4,021.60 | -2,374.12 | -- | -- | 0.0127 | -- | 77.78 | -24.57 | -19.00 | -- | -57.50 | -- |
| Nuo Therapeutics Inc | 2.61m | -2.43m | 76.77m | -- | -- | -- | -- | 29.40 | -0.0517 | -0.0517 | 0.0555 | -0.0088 | 1.43 | 4.19 | 5.32 | -- | -133.29 | -121.45 | -289.99 | -243.05 | 70.38 | 78.52 | -93.06 | -424.19 | 1.00 | -17,110.33 | -- | -- | 124.34 | 56.34 | 26.73 | -- | -- | -- |
| TuHURA Biosciences Inc | 0.00 | -43.77m | 78.94m | 19.00 | -- | 4.04 | -- | -- | -1.60 | -1.60 | 0.00 | 0.3273 | 0.00 | -- | -- | 0.00 | -286.97 | -- | -456.76 | -- | -- | -- | -- | -- | -- | -9.01 | 0.0286 | -- | -- | -- | -- | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Maia Biotechnology Inc's reporting currency: US Dollar USD
6.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 944.12k | 2.55% |
| Centric Wealth Management LLCas of 31 Dec 2025 | 586.40k | 1.58% |
| Geode Capital Management LLCas of 30 Sep 2025 | 271.06k | 0.73% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 199.31k | 0.54% |
| Marshall Wace LLPas of 30 Sep 2025 | 110.47k | 0.30% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 100.18k | 0.27% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 75.55k | 0.20% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 39.03k | 0.11% |
| Bridgeway Capital Management LLCas of 30 Sep 2025 | 36.00k | 0.10% |
| Ritholtz Wealth Management LLCas of 31 Dec 2025 | 23.07k | 0.06% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
